Biodesix Inc. logo

Biodesix Inc. (BDSX)

Market Open
12 Jun, 13:57
NASDAQ (NMS) NASDAQ (NMS)
$
14. 92
+0.12
+0.8108%
$
134.31M Market Cap
- P/E Ratio
- Div Yield
2,688 Volume
-0.42 Eps
$ 14.8
Previous Close
Investors:
Add Transaction
Day Range
14.8 15.28
Year Range
5 20.21
Want to track BDSX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
3 Medical Service Industry Stocks Thriving Amid Workforce Challenges

3 Medical Service Industry Stocks Thriving Amid Workforce Challenges

BTSG, BDSX and HQY stand to benefit as digital health, healthcare analytics and nursing care growth offset workforce strains.

Zacks | 4 days ago
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade

Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade

The mean of analysts' price targets for Biodesix (BDSX) points to a 104.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks | 2 weeks ago
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?

Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?

The mean of analysts' price targets for Biodesix (BDSX) points to a 103.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks | 1 month ago
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates

Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to a loss of $1.6 per share a year ago.

Zacks | 1 month ago
Wall Street Analysts See an 86.45% Upside in Biodesix (BDSX): Can the Stock Really Move This High?

Wall Street Analysts See an 86.45% Upside in Biodesix (BDSX): Can the Stock Really Move This High?

The mean of analysts' price targets for Biodesix (BDSX) points to an 86.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks | 2 months ago
Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?

Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?

Here is how Biodesix, Inc. (BDSX) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.

Zacks | 2 months ago
Biodesix, Inc. (BDSX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Biodesix, Inc. (BDSX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Biodesix, Inc. (BDSX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Seekingalpha | 3 months ago
Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet

Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet

The mean of analysts' price targets for Biodesix (BDSX) points to an 111.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks | 3 months ago
Are Medical Stocks Lagging Biodesix (BDSX) This Year?

Are Medical Stocks Lagging Biodesix (BDSX) This Year?

Here is how Biodesix, Inc. (BDSX) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

Zacks | 3 months ago
Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript

Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript

Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript

Seekingalpha | 3 months ago
Biodesix, Inc. (BDSX) Reports Q4 Loss, Beats Revenue Estimates

Biodesix, Inc. (BDSX) Reports Q4 Loss, Beats Revenue Estimates

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $1.2 per share a year ago.

Zacks | 3 months ago
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 325.67%: Here's is How to Trade

Wall Street Analysts Believe Biodesix (BDSX) Could Rally 325.67%: Here's is How to Trade

The mean of analysts' price targets for Biodesix (BDSX) points to a 325.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks | 6 months ago
Loading...
Load More